<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues</title>
				<funder ref="#_ejbPSgG #_jMcNyZC #_mDRdG6y #_bktzc9j">
					<orgName type="full">National Institute on Drug Abuse</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Elsevier BV</publisher>
				<availability status="unknown"><p>Copyright Elsevier BV</p>
				</availability>
				<date type="published" when="2012-09-01">2012 September 1.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Ph.D</roleName><forename type="first">Kathryn</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Addiction Research</orgName>
								<orgName type="department" key="dep2">Dept. Pharmacology and Toxicology</orgName>
								<orgName type="department" key="dep3">Medical Branch</orgName>
								<orgName type="institution">University of Texas</orgName>
								<address>
									<settlement>Galveston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">G</forename><surname>Fox</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Addiction Research</orgName>
								<orgName type="department" key="dep2">Dept. Pharmacology and Toxicology</orgName>
								<orgName type="department" key="dep3">Medical Branch</orgName>
								<orgName type="institution">University of Texas</orgName>
								<address>
									<settlement>Galveston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Noelle</forename><forename type="middle">C</forename><surname>Anastasio</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Addiction Research</orgName>
								<orgName type="department" key="dep2">Dept. Pharmacology and Toxicology</orgName>
								<orgName type="department" key="dep3">Medical Branch</orgName>
								<orgName type="institution">University of Texas</orgName>
								<address>
									<settlement>Galveston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcy</forename><forename type="middle">J</forename><surname>Bubar</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Addiction Research</orgName>
								<orgName type="department" key="dep2">Dept. Pharmacology and Toxicology</orgName>
								<orgName type="department" key="dep3">Medical Branch</orgName>
								<orgName type="institution">University of Texas</orgName>
								<address>
									<settlement>Galveston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sonja</forename><forename type="middle">J</forename><surname>Stutz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Addiction Research</orgName>
								<orgName type="department" key="dep2">Dept. Pharmacology and Toxicology</orgName>
								<orgName type="department" key="dep3">Medical Branch</orgName>
								<orgName type="institution">University of Texas</orgName>
								<address>
									<settlement>Galveston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><forename type="middle">Gerard</forename><surname>Moeller</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Scott</forename><forename type="middle">R</forename><surname>Gilbertson</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">University of Houston</orgName>
								<address>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sharon</forename><surname>Rosenzweig-Lipson</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Pfizer Global Research and Development</orgName>
								<address>
									<settlement>Neuroscience, Groton</settlement>
									<region>CT</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">UTMB Center for Addiction Research</orgName>
								<orgName type="institution" key="instit2">University of Texas Medical Branch</orgName>
								<address>
									<postCode>77550-0615</postCode>
									<settlement>Galveston</settlement>
									<region>Texas</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Neuropharmacology</title>
						<title level="j" type="abbrev">Neuropharmacology</title>
						<idno type="ISSN">0028-3908</idno>
						<imprint>
							<publisher>Elsevier BV</publisher>
							<biblScope unit="volume">61</biblScope>
							<biblScope unit="issue">3</biblScope>
							<biblScope unit="page" from="513" to="523"/>
							<date type="published" when="2012-09-01">2012 September 1.</date>
						</imprint>
					</monogr>
					<idno type="MD5">625BDB58995B74FF0058E8CCDDF73641</idno>
					<idno type="DOI">10.1016/j.neuropharm.2011.04.034</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-04-21T20:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Serotonin (5-HT) controls affective and motivational aspects of palatable food and drug reward and the 5-HT 2C receptor (5-HT 2C R) has emerged as a key regulator in this regard.</s><s>We have evaluated the efficacy of a selective 5-HT 2C R agonist, WAY 163909, in cocaine and sucrose selfadministration and reinstatement assays employing parallel experimental designs in free-fed rats.</s><s>WAY 163909 dose-dependently reduced the reinforcing efficacy of cocaine (ID 50 =1.19</s><s>mg/kg) and sucrose (ID 50 =0.7 mg/kg) as well as reinstatement (ID 50 =0.5 mg/kg) elicited by exposure to cocaine-associated contextual cues, but not sucrose-associated contextual cues.</s><s>The ID 50 of WAY 163909 predicted to decrease the reinforcing efficacy of cocaine or sucrose as well as reinstatement upon exposure to cocaine-associated cues was ~5-12-fold lower than that predicted to suppress horizontal ambulation (ID 50 = 5.89 mg/kg) and ~2-5-fold lower than that predicted to suppress vertical activity (ID 50 = 2.3 mg/kg).</s><s>Thus, selective stimulation of the 5-HT 2C R decreases the reinforcing efficacy of cocaine and sucrose in freely-fed rats, but differentially alters the incentive-salience value of cocaine-vs.</s><s>sucrose-associated cues at doses that do not impair locomotor activity.</s><s>Future research is needed to tease apart the precise contribution of 5-HT 2C R neurocircuitry in reward and motivation and the learning and memory processes that carry the encoding for associations between environmental cues and consumption of rewarding stimuli.</s><s>A more complete preclinical evaluation of these questions will ultimately allow educated proof-ofconcept trials to test the efficacy of selective 5-HT 2C R agonists as adjunctive therapy in chronic health maladies including obesity, eating disorders and drug addiction.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">INTRODUCTION</head><p><s>Survival is ensured by neural circuits engaged by basic needs (e.g., food, water) and states (e.g., hunger, thirst) that motivate the organism to sustain important biological functions.</s><s>Brain motivational systems are sensitive to endogenous and exogenous stimuli that become linked to natural and drug rewards, and neuroplasticity in these circuits engender affective states that powerfully drive such behaviors as bingeing on palatable food (e.g., fat, sucrose) or abused drugs (e.g., cocaine).</s><s>A complex appetitive process links the motivation to consume (e.g., hunger) with the palatability and incentive salience of the rewarding stimulus (drug or food) and its associated conditioned cue properties as well as with the satiety signals that terminate further intake <ref type="bibr" target="#b23">(Halford and Harrold, 2008)</ref>.</s><s>Studies over the last 20 years have identified cellular and behavioral mechanisms of these appetitive processes to include dopamine, glutamate, and their intracellular signaling webs in the limbiccorticostriatal-hypothalamic circuit <ref type="bibr" target="#b29">(Kelley, 2004)</ref>.</s><s>Serotonin (5-HT) is additionally important in the control over the affective and motivational aspects of palatable food and drug reward, which has been described to occur at the level of satiety <ref type="bibr" target="#b26">(Hewitt, et al., 2002;</ref><ref type="bibr" target="#b35">Lyness, et al., 1980;</ref><ref type="bibr" target="#b2">Blundell, et al., 1980)</ref> as well as palatability or reinforcing efficacy <ref type="bibr" target="#b70">(Wogar, et al., 1991)</ref>.</s><s>In particular, there is a growing literature based upon genetic and pharmacological manipulations that the serotonin 5-HT 2C receptor (5-HT 2C R) signaling regulates such neurobehavioral processes which may underlie important chronic health maladies including obesity, eating disorders and drug addiction <ref type="bibr" target="#b22">(Halford, et al., 2010;</ref><ref type="bibr" target="#b5">Bubar and Cunningham, 2008;</ref><ref type="bibr" target="#b59">Steiger, 2004)</ref>.</s></p><p><s>The selective activation of signaling through the 5-HT 2C R has been associated with reduced feeding and decreased body weight in animals <ref type="bibr" target="#b17">(Fletcher, et al., 2009;</ref><ref type="bibr" target="#b9">Clifton, et al., 2000)</ref> and most recently in humans <ref type="bibr" target="#b57">(Smith, et al., 2010;</ref><ref type="bibr" target="#b56">Smith, et al., 2009)</ref>.</s><s>The constitutive knockout of the 5-HT 2C R in mice results in hyperphagia <ref type="bibr" target="#b62">(Tecott, et al., 1995)</ref> and increased intake of cocaine <ref type="bibr" target="#b51">(Rocha, et al., 1998)</ref>; the phenotype also includes adult-onset obesity and depressed metabolic rate <ref type="bibr" target="#b62">(Tecott, et al., 1995)</ref>.</s><s>Selective 5-HT 2C R antagonists have been shown to increase baseline food intake <ref type="bibr" target="#b3">(Bonhaus, et al., 1997;</ref><ref type="bibr" target="#b63">Thomsen, et al., 2008)</ref> (but see, <ref type="bibr" target="#b26">Hewitt, et al., 2002)</ref> in the same dose range shown to block the effects of a 5-HT 2C R selective agonist to decrease feeding <ref type="bibr" target="#b63">(Thomsen, et al., 2008;</ref><ref type="bibr" target="#b20">Grottick, et al., 2000)</ref>.</s><s>Analogous to these findings with palatable food reward, rates for responding for cocaine in a self-administration task were suppressed by pretreatment with a preferential 5-HT 2C R agonist and enhanced by a selective 5-HT 2C R antagonist <ref type="bibr" target="#b15">(Fletcher, et al., 2008;</ref><ref type="bibr" target="#b20">Grottick, et al., 2000)</ref>, suggesting an important role for the 5-HT 2C R in control of the overt rewarding efficacy of cocaine.</s><s>A preferential 5-HT 2C R agonist also suppressed intake of nicotine <ref type="bibr">(Grottick, et al., 2001)</ref> and alcohol <ref type="bibr" target="#b64">(Tomkins, et al., 2002)</ref>.</s><s>The mechanisms are complex but a role for the 5-HT 2C R to enhance satiety and/or suppress incentive-motivational aspects of appetitive food or drug reinforcers are both supported <ref type="bibr" target="#b16">(Fletcher, et al., 2010;</ref><ref type="bibr" target="#b6">Burbassi and Cervo, 2008;</ref><ref type="bibr" target="#b50">Rocha, et al., 2002;</ref><ref type="bibr" target="#b68">Vickers, et al., 1999;</ref><ref type="bibr" target="#b26">Hewitt, et al., 2002;</ref><ref type="bibr" target="#b16">Fletcher, et al., 2010)</ref>.</s></p><p><s>There is much less known about the role of serotonin in general, and the 5-HT 2C R in specific, to regulate drug-or food-seeking behavior upon exposure to environmental stimuli previously associated with drug or palatable food, respectively.</s><s>Loss of 5-HT neurons after intraventricular infusion of a 5-HT neurotoxin decreased cocaine-seeking but enhanced sucrose-seeking during extinction in freely-fed rats previously trained to self-administer cocaine or sucrose, respectively <ref type="bibr" target="#b67">(Tran-Nguyen, et al., 2001)</ref>.</s><s>The selective 5-HT reuptake inhibitor fluoxetine was shown to suppress palatable food intake most potently in freely-fed female rats pre-exposed to food cues <ref type="bibr" target="#b8">(Cifani, et al., 2009)</ref>.</s><s>The preferential 5-HT 2C R agonists MK 212 <ref type="bibr" target="#b43">(Neisewander and Acosta, 2007)</ref> and Ro 60-0175 <ref type="bibr" target="#b15">(Fletcher, et al., 2008)</ref> have been shown to suppress cue-evoked reinstatement in cocaine self-administration.</s><s>However, the interpretation of findings across studies and the development of an overarching appreciation of how 5-HT 2C R neurocircuitry controls drug or palatable food intake or "relapse" in the face of reward-related cues are hampered by two issues.</s><s>The first challenge is that selective agonists with singular high affinity and efficacy for the 5-HT 2C R have only recently become commercially available.</s><s>The second challenge is that few studies have established the sensitivity of palatable reward vs. reward-related cues to a specific manipulation of 5-HT 2C R function employing comparable assay methodologies in a given species [for a recent review of these methodologies, see <ref type="bibr" target="#b41">(Nair, et al., 2009)</ref>].</s></p><p><s>The 5-HT 2C receptor (5-HT 2C R) shares high homology with the two other members (5-HT 2A R, 5-HT 2B R) of the 5-HT 2 R family of G-protein-coupled receptors.</s><s>Until recently, only "preferential" 5-HT 2C R ligands which frequently display affinity (agonists, antagonist) and/or efficacy (agonists) at the 5-HT 2A R and 5-HT 2B R have been available and some experimental outcomes with non-selective 5-HT 2C R ligands have led to ambiguous conclusions concerning the biological roles for this receptor.</s><s>Furthermore, as 5-HT 2A R or 5-HT 2B R agonists would be expected to evoke hallucinations <ref type="bibr" target="#b45">(Nichols, 2004)</ref> or cardiac valvulopathy <ref type="bibr" target="#b13">(Fitzgerald, et al., 2000;</ref><ref type="bibr" target="#b54">Roth, 2007)</ref>, respectively, therapeutically-useful 5-HT 2C R agonists must not have demonstrable efficacy at 5-HT 2A R or 5-HT 2B R in vivo.</s><s>Such selectivity has been difficult to achieve, providing challenges to the careful preparation of preclinical analyses in support of ultimate proof-of-concept studies of selective 5-HT 2C R agonists in humans for treatment of obesity, eating disorders or addiction.</s></p><p><s>In a compound series recently developed at Wyeth Research, vabicaserin (SCA-136) was identified as a selective 5-HT 2C R full agonist (K i = 3 nM; efficacy 100% relative to 5-HT), a 5-HT 2B R antagonist (IC 50 = 29 nM) and a very weak 5-HT 2A R antagonist (IC 50 = 1,650 nM) <ref type="bibr">(Rosenzweig-Lipson, et al., 2007a;</ref><ref type="bibr">Tong, et al., 2010a;</ref><ref type="bibr">Tong, et al., 2010b)</ref>.</s><s>Vabicaserin has been in clinical trials to evaluate antipsychotic potential (www.clinicaltrials.gov).</s><s>WAY 163909 is chemically-similar to vabicaserin with high affinity (K i =10.5 nM) and full efficacy (90% relative to 5-HT) at the 5-HT 2C R. WAY 163909 exhibits a low affinity (K i =212 nM) at the 5-HT 2A R, and no efficacy and is a weak partial agonist at the 5-HT 2B R at concentrations 23-fold greater <ref type="bibr" target="#b12">(Dunlop, et al., 2005)</ref>.</s><s>In the present study, we have evaluated the efficacy of WAY 163909 to suppress the reinforcing effects of the abused psycho stimulant cocaine and the palatable food sucrose as well as cueevoked reinstatement in parallel experimental designs in freely-fed rats.</s><s>To date, the only other preferential 5-HT 2C R agonists to be profiled in a some what similar fashion are MK 212 and Ro 60-0175; Table <ref type="table" target="#tab_1">1</ref> provides a comparison of affinity and efficacy at the three 5-HT 2 R for MK 212, Ro 60-0175 and WAY 163909.</s></p><p><s>The present study investigated the hypothesis that WAY 163909 would suppress cocaine or sucrose self-administration or cue-evoked reinstatement in freely-fed male rats under conditions that minimized potential confounds imposed by food (or water) restriction [see <ref type="bibr" target="#b20">(Grottick, et al., 2000;</ref><ref type="bibr" target="#b14">Fletcher, et al., 2002;</ref><ref type="bibr" target="#b44">Nic Dhonnchadha, et al., 2009)</ref>, for discussion] and operant pretraining for an appetitive reinforcer <ref type="bibr" target="#b20">(Grottick, et al., 2000;</ref><ref type="bibr" target="#b14">Fletcher, et al., 2002;</ref><ref type="bibr" target="#b44">Nic Dhonnchadha, et al., 2009)</ref>.</s><s>The doses of cocaine for reliable self-administration and reinstatement are well-established in the literature <ref type="bibr" target="#b44">(Nic Dhonnchadha, et al., 2009;</ref><ref type="bibr" target="#b7">Carroll and Lac, 1997;</ref><ref type="bibr" target="#b44">Nic Dhonnchadha, et al., 2009;</ref><ref type="bibr" target="#b46">Pentkowski, et al., 2010;</ref><ref type="bibr" target="#b20">Grottick, et al., 2000;</ref><ref type="bibr" target="#b6">Burbassi and Cervo, 2008;</ref><ref type="bibr" target="#b14">Fletcher, et al., 2002)</ref> and we chose to compare cocaine to a sucrose reinforcer under the same assay conditions because preliminary observations indicated that freely-fed rats would establish levels of active lever presses for sucrose pellets under an ultimate fixed ratio (FR) 5 schedule that were comparable to those seen for a cocaine self-administration.</s><s>Employing these analogous assay methodologies in the rat allowed us to establish the differential sensitivity of a natural (sucrose) and drug (cocaine) reward vs. reward-related cues to pretreatment with a highly-selective and efficacious 5-HT 2C R agonist and to compare with the body of literature available for the preferential 5-HT 2C R agonists MK 212 <ref type="bibr" target="#b43">(Neisewander and Acosta, 2007)</ref> and Ro 60-0175 <ref type="bibr">(Higgins, et al., 2001;</ref><ref type="bibr">Grottick, et al., 2001;</ref><ref type="bibr" target="#b15">Fletcher, et al., 2008;</ref><ref type="bibr" target="#b16">Fletcher, et al., 2010)</ref>.</s><s>We report that cocaine-taking and especially cocaine-seeking are highly sensitive to suppression by WAY 163909.</s><s>Interestingly, sucrose-taking is also potently suppressed by WAY 163909, but sucrose-seeking is relatively insensitive to the selective 5-HT 2C R agonist in freely-fed rats.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Animals</head><p><s>A total of 91 male Sprague-Dawley rats (Harlan, Inc., Indianapolis, IN, USA) weighing 225-325g at the start of the experiments were used.</s><s>Rats were allowed to acclimate for 5-7 days in a colony room at a constant temperature (21-23°C) and humidity (45-50%) on a 12 hr light-dark cycle (lights on 0700-1900 hr).</s><s>Rats were housed either two (selfadministration studies) or four rats per cage (locomotor activity studies) with food and water ad libitum throughout all phases of the studies.</s><s>All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals <ref type="bibr">(National Research Council, 1996)</ref> and with the approval of the Institutional Animal Care and Use Committee at University of Texas Medical Branch.</s><s>All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques, when available.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Drugs</head><p><s>WAY 163909 <ref type="bibr">[(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]</ref>diazepino <ref type="bibr">[6,7,1hi]</ref>indole; Wyeth Research, Princeton, NJ, USA] was dissolved in 0.9% NaCl.</s><s><ref type="bibr">SB242084 [6-chloro-5-methyl-1-[[2-(2-methylpyrid-3-yloxy)</ref> pyrid-5yl]carbamoyl]indolinedihydrochloride; Sigma Chemical Co., St. Louis, MO, USA] was dissolved in 0.9% NaCl containing 10 mM citric acid (Sigma Chemical Co.) and 8% 2hydroxypropyl-β-cyclodextrin (Trappsol ® Hydroxpropyl Beta Cyclodextrin, Pharmaceutical Grade, Cyclodextrin Technologies Development Inc., High Springs, FL, USA) with the final pH of the solution adjusted to 5.6.</s><s>(-)-Cocaine (National Institutes on Drug Abuse, Research Triangle Park, NC, USA) was dissolved in 0.9% NaCl.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Locomotor Activity Studies</head><p><s>2.3.1 Apparatus-Locomotor activity was monitored and quantified under low light conditions using a modified open field activity system (San Diego Instruments, San Diego, CA, USA).</s><s>Clear Plexiglass chambers (40 × 40 × 40 cm) were surrounded by a 4 × 4 photobeam matrix positioned 4 cm from chamber floor.</s><s>Consecutive photobeam breaks within the central 16 × 16 cm of the activity monitor were recorded as central ambulation.</s><s>Peripheral ambulation was counted as consecutive beam breaks in the surrounding perimeter.</s><s>Central and peripheral ambulations were summed to provide a measure of total horizontal ambulation.</s><s>Vertical activity was also recorded using a row of 16 photobeams, positioned 16 cm from the activity monitor floor; breaks in these beams indicated vertical (rearing) activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.3.2</head><p><s>Procedures-Rats in locomotor activity studies (n=16) were acclimated to the colony room 5-7 days prior to the start of handling protocols.</s><s>Following seven days of handling, rats were habituated to the activity monitors for 60 min.</s><s>Twenty four hours later, rats received the first dose of vehicle (saline, 1 ml/kg, i.p.) or WAY 163909 (0.3, 1, 3 or 10 mg/kg, i.p.) immediately prior to placement in activity monitors; activity was assessed for 60 min.</s><s>Using a repeated measures design, rats were tested every three days such that all rats received vehicle and all three doses of WAY 163909 in a counterbalanced manner.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Self Administration Studies</head><p><s>2.4.1 Surgery-Implantations of intravenous catheters with back mounts were performed under anesthesia with a cocktail containing 8.6 mg/kg ofxylazine, 1.5 mg/kg of acepromazine, and 43 mg/kg of ketamine in bacteriostatic saline.</s><s>Small incisions were made in the right posterior neck and just below the left shoulder blade to expose the jugular vein and to insert the catheter base, respectively.</s><s>A subcutaneous burrow was made between the two incisions, and the catheter apparatus was pulled through this burrow.</s><s>The catheter was composed of Silastic tubing (Dow Corning, Midland MI, USA) connected to a bent 22gauge metal cannula encased within a plastic screw connector (Plastics One, Roanoke, VA, USA) at one end and affixed with a small ball of silicone 3.5 cm from the other end.</s><s>The distal end of the catheter was inserted into the jugular vein until flush with the silicone ball, terminating outside the right atrium.</s><s>The catheter was secured to the vein with sutures (SP116 braided silk non-absorbable 4.0; Surgical Specialties Corporation, Reading, PA, USA) on both sides of the silicone ball.</s><s>The incision was then sutured (Monomid nylon nonabsorbable 4.0; CP Medical, Portland, OR, USA).</s><s>The cannula base was encased with dental acrylic and a small mesh circle (3 cm × 3 cm; Polypro mesh 500 micron, Small Parts, Inc., Seattle, WA, USA) affixed to the bottom, which was pulled thru the small incision in the back.</s><s>The remaining opening was then sutured (Monomid nylon non-absorbable 4.0; CP Medical).</s><s>Daily flushes with a solution of 0.1 ml of bacteriostatic saline containing heparin sodium (10U/mL; American Pharmaceutical Partners, East Schaumburg, IL, USA), streptokinase (0.67 mg/mL; Sigma Chemical) and ticarcillin disodium (66.67 mg/mL; Research Products International, Mt.</s><s>Prospect, IL, USA) were performed after each cocaine self-administration session to maintain catheter patency.</s><s>Proper catheter function was verified periodically throughout the experiment by intravenous administration of 10 mg/kg of methohexital sodium (Monarch Pharmaceuticals Inc., Bristol, TN, USA), a dose sufficient to briefly anesthetize the animal only when administered intravenously.</s><s>All rats were allowed at least five days of recovery after surgery before initiation of selfadministration training.</s><s>Rats trained in sucrose self-administration were naïve at the start of the experiment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.4.2</head><p><s>Apparatus-Standard operant conditioning chambers (Med-Associates, Inc., St. Albans, VT, USA) housed in ventilated sound-attenuating cubicles with fans (Med-Associates, Inc.) were utilized for both the cocaine and sucrose self-administration studies.</s><s>Each chamber was equipped with two retractable response levers, a stimulus light above each response lever, a house light opposite the levers, and a magazine-type pellet dispenser.</s><s>Cocaine infusions were delivered by a syringe attached to an infusion pump (Med Associates, Inc.) located outside the cubicle.</s><s>The infusion pumps were connected to liquid swivels (Instech, Plymouth Meeting, PA, USA) that were fastened to the catheters via polyethylene 20 tubing encased inside a metal spring leash (Plastics One).</s><s>Sucrose pellets (45 mg; Bio-Serv, Frenchtown, NJ, USA) were delivered into a pellet receptacle located between the two levers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.3">Experimental Design</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.3.1">Effects of WAY 163909 and SB 242084 during cocaine self-administration:</head><p><s>Cocaine self-administration training consisted of daily 60-min sessions during which rats (n=8) were trained to press the active lever to obtain a cocaine infusion (0.25 mg/kg/0.1 mL infusion).</s><s>Animals were not food restricted or trained on an operant task prior to commencement of self-administration and no cocaine priming infusions were given during the experiment.</s><s>Schedule completions on the active lever resulted in simultaneous illumination of the house and stimulus lights, followed 1 sec later by activation of the infusion pump.</s><s>Rats received a 0.1 mL cocaine infusion delivered over a 6-sec period, after which the pump and stimulus light (conditioned stimuli paired with delivery of cocaine) were inactivated simultaneously.</s><s>The house light remained illuminated for a 20-sec timeout period, during which lever presses had no scheduled consequences.</s><s>Responses on the inactive lever were recorded but had no scheduled consequences.</s><s>Rats were initially trained on an FR 1 schedule of cocaine reinforcement until they met a criterion of seven infusions/hr for at least three sessions with &lt;10% variation in the number of infusions received for three consecutive sessions.</s><s>After reaching this acquisition criterion and demonstrating stable cocaine self-administration on an FR1 schedule of reinforcement, rats progressed to an FR 3 schedule of reinforcement, and then on to an FR 5 schedule of reinforcement once the same criterion levels were met.</s><s>Once stable cocaine self-administration on an FR 5 schedule was achieved (i.e., &lt;10% variation in the number of infusions received for three consecutive sessions), the efficacy and selectivity of WAY 163909 to alter response for cocaine selfadministration was assessed.</s><s>Rats were administered vehicle (saline; 1mL/kg; 15 min) or WAY 163909 (0.5, 1 or 2 mg/kg, i.p.; 15 min) prior to self-administration sessions, according to a within-subjects design.</s><s>To investigate the selectivity of WAY 163909 for the 5-HT 2C receptor, the same rats were administered the 5-HT 2C receptor antagonist SB 242084 (0.5 mg/kg, i.p.; 30 min) plus vehicle (saline; 1 mL/kg; 15 min) or WAY 163909 (2 mg/kg, i.p.; 15 min) prior to self-administration sessions, according to a within-subjects design.</s><s>The order of injections was counterbalanced and a minimum of two intervening sessions of cocaine self-administration (0.25 mg/kg/0.1 mL infusion) occurred between each drug challenge to assure stability of baseline responding.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.3.2">Effects of WAY 163909 on cue-induced reinstatement in rats trained to selfadminister cocaine:</head><p><s>A separate cohort of rats (n=34) was utilized to assess the effects of WAY 163909 on cue-induced reinstatement following cocaine self-administration.</s><s>Cocaine self-administration training consisted of daily 180-min sessions during which rats were trained to press the active lever to obtain a cocaine infusion (0.75 mg/kg/0.1 mL infusion) on an FR 1 schedule of reinforcement before progressing to an FR 5 schedule.</s><s>Animals were not food restricted or trained on an operant task prior to commencement of selfadministration and no cocaine priming infusions were given during the experiment.</s><s>Rats that met the criterion for stable self-administration (&lt;10% variation in the number of infusions received for three consecutive sessions) were subjected to daily 60-min extinction sessions, during which active and inactive lever presses were recorded but had no scheduled consequences (i.e., did not activate the infusion pump or result in presentation of the stimulus light).</s><s>Once rats achieved the extinction criterion of response rates &lt;15 total responses/hr for three consecutive sessions, the effects of WAY 163909 on cue-induced reinstatement of cocaine-seeking behavior were examined.</s><s>The criterion of &lt;15 responses/hr as indicative of extinction level responding is commonly employed in self-administration studies and corresponds to approximately 15% of responding during active cocaine selfadministration <ref type="bibr" target="#b32">(Leri, et al., 2002;</ref><ref type="bibr" target="#b44">Nic Dhonnchadha, et al., 2009)</ref>.</s><s>To initiate reinstatement sessions, one non-contingent presentation of the cocaine-paired cues (pump and stimulus light) was given.</s><s>During the 60-min test session, responses on the active lever were reinforced by presentation of the cocaine-paired cues on an FR 1 schedule.</s><s>To assess the effects of WAY 163909 on cue-induced reinstatement of cocaine-seeking behavior, rats were injected with saline (1 mL/kg; 15 min) or WAY 163909 (0.5, 1, or 1.5 mg/kg, i.p.; 15 min) before the start of the reinstatement session according to a between-subjects, counterbalanced design (n=8-9/group).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.3.3">Effects of WAY 163909 and SB 242084 on sucrose self-administration:</head><p><s>Sucrose self-administration training consisted of daily 60-min sessions during which rats (n=8) were trained to press the active lever to obtain a 45 mg sucrose pellet.</s><s>Experimental parameters were identical to those described in Section 2.4.3.1, above, except for substitution of a single 45 mg sucrose pellet as the reinforce.</s><s>Animals were not food restricted or trained on an operant task prior to commencement of self-administration and no sucrose priming events were given during the experiment.</s><s>Upon reaching stability on the FR 5 schedule, the efficacy and selectivity of WAY 163909 to alter response for sucrose self-administration was assessed, as described above (Section 2.4.3.1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.3.4">Effects of WAY 163909 on cue-induced reinstatement in rats trained to selfadminister sucrose pellets:</head><p><s>A separate cohort of rats (n=25) was utilized to assess the effects of WAY 163909 on cue-induced reinstatement following sucrose self-administration.</s><s>Sucrose self-administration training consisted of daily 180-min sessions during which rats were trained to press the active lever to obtain a 45 mg sucrose pellet on an FR 1 schedule of reinforcement before progressing to an FR 5 schedule.</s><s>Experimental parameters were identical to those described in Section 2.4.3.2 above, except for substitution of a single 45 mg sucrose pellet as the reinforcer.</s><s>Animals were not food restricted or trained on an operant task prior to commencement of self-administration and no sucrose priming events were given during the experiment.</s><s>To assess the effects of WAY 163909 on cue-induced reinstatement of sucrose-seeking behavior, rats were injected with saline (1 mL/kg; 15 min) or WAY 163909 (0.5 or 1.5 mg/kg,i.p.; 15 min) before the start of the reinstatement session according to a between-subjects, counterbalanced design (n=8-9/group).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">Statistical analysis</head><p><s>Locomotor activity data were analyzed and are presented as mean total horizontal ambulation or vertical activity (± SEM) over the 60-min session (Figs.</s><s>1A Inset, 1B Inset) or within the 15, 30, 45 and 60 min time bins (Figs.</s><s><ref type="figure" target="#fig_0">1A,</ref><ref type="figure" target="#fig_0">1B</ref>).</s><s>The main effect of treatment (WAY 163909 dose) on horizontal ambulation or vertical activity was analyzed using a repeated measures, one-way analysis of variance (ANOVA) using the general linear model (GLM) procedure (SAS for Windows, Version 8.2, SAS Institute, Inc., Cary, NC, USA).</s><s>A two-way ANOVA for repeated measures for the factors of treatment (WAY 163909 dose) and time (15, 30, 45 or 60 min) was also conducted.</s><s>Subsequent a priori comparisons between means of total horizontal ambulation or total vertical activity were made using the Dunnett's procedure, with vehicle as the comparator.</s><s>The four parameter logistic nonlinear regression model equation (Sigma Plot, Version 11.0, Systat Software, Inc., Chicago, IL, USA) was used to estimate the dose of WAY 163909 predicted to decrease horizontal ambulation or vertical activity by 50% (ID 50 ) (Table <ref type="table">2</ref>) <ref type="bibr" target="#b49">(Ratkowsky and Reedy, 1986;</ref><ref type="bibr" target="#b61">Tallarida and Murray, 1987)</ref>.</s><s>All statistical analyses were conducted with an experiment wise error rate of α=0.05.</s></p><p><s>The data from the self-administration, extinction and reinstatement phases were analyzed separately and presented as mean ± SEM.</s><s>A one-way ANOVA (SAS for Windows, V8.2) for repeated measures was used to analyze the dependent measures of the total number of 1) active lever responses/session, 2) inactive lever presses/session, and 3) number of cocaine infusions or sucrose pellets/session during the self-administration phase and the total number of responses/session on the 4) previously-active, or 5) -inactive lever during the extinction phase.</s><s>A one-way ANOVA for repeated measures (cocaine-or sucrose-taking) or independent groups (cocaine-or sucrose-seeking) was used to analyze the effects of pretreatment with WAY 163909 on the total number of 1) responses/session on the previously-active, or 2) -inactive lever, and 3) cocaine infusions/session or sucrose pellets/ session, and 4) the latency to respond on the previously-active lever during the selfadministration and the cue-induced reinstatement phase.</s><s>A priori comparisons for WAY 163909 pretreatment were carried out with Student-Newman-Keuls test with the alpha level set at p&lt; 0.05.</s><s>A repeated measures one-way ANOVA was employed to compare responding on the previously-active lever over the last three sessions of extinction with responding observed following vehicle pretreatment during reinstatement sessions.</s><s>The four parameter logistic nonlinear regression model equation (Sigma Plot, Version 11, SystatSoftware, Inc.) was used to estimate the dose of WAY 163909 predicted to decrease lever presses during cocaine or sucrose self-administration and reinstatement sessions by 50% (ID 50 ), for each (Table <ref type="table">2</ref>) <ref type="bibr" target="#b49">(Ratkowsky and Reedy, 1986;</ref><ref type="bibr" target="#b61">Tallarida and Murray, 1987)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">WAY 163909 evokes a dose-dependent suppression of locomotor activity</head><p><s>A main effect of treatment (F (4,66) = 10.33,</s><s>p &lt;0.001), time (F (3,66) = 253.42,</s><s>p &lt;0.001) and a treatment × time interaction (F (12,198) = 5.23, p &lt;0.001) was observed for horizontal ambulation divided into four 15 min time bins (Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>WAY 163909 at 0.3 mg/kg significantly reduced horizontal ambulation versus vehicle during the third interval (45 min), while 3 mg/kg of WAY 163909 significantly reduced horizontal ambulation versus vehicle at the first (15 min), second (30 min) and third intervals (45 min) (p &lt; 0.05; Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>WAY 163909 at 10 mg/kg significantly reduced horizontal ambulation versus vehicle during each of the four 15 min intervals examined (p &lt; 0.05; Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>A main effect of WAY 163909 treatment was observed for horizontal ambulation (F 4,66 = 10.65,</s><s>p &lt; 0.001; Fig. <ref type="figure" target="#fig_0">1A,</ref><ref type="figure">inset</ref>) summed across the 60-min test session; a priori comparisons using the Dunnett's procedure revealed that 3 and 10 mg/kg of WAY 163909 significantly reduced horizontal ambulation versus vehicle (p &lt; 0.05; Fig. <ref type="figure" target="#fig_0">1A,</ref><ref type="figure">inset</ref>).</s><s>The dose of WAY 163909 predicted to decrease horizontal ambulation by 50% (ID 50 ) was 5.89 mg/kg (Table <ref type="table">2</ref>).</s></p><p><s>A main effect of treatment (F (4,66) = 6.16, p &lt; 0.001), time (F 3,66 = 146.02,</s><s>p&lt; 0.001) and a significant treatment × time interaction (F (12,198) = 2.73, p &lt;0.01) was observed for vertical activity divided into four 15 min intervals (Fig. <ref type="figure" target="#fig_0">1B</ref>).</s><s>WAY 163909 at 10 mg/kg significantly reduced vertical activity versus vehicle during the first three 15 min intervals (p &lt; 0.05; Fig. <ref type="figure" target="#fig_0">1B</ref>).</s><s>A main effect of WAY 163909 treatment was observed for vertical activity (F 4,66 = 5.66, p &lt; 0.001; Fig. <ref type="figure" target="#fig_0">1B Inset</ref>) summed across the 60-min test session; a priori comparisons using the Dunnett's procedure revealed that 10mg/kg of WAY 163909 significantly reduced vertical activity versus vehicle (p &lt; 0.05; Fig. <ref type="figure" target="#fig_0">1B,</ref><ref type="figure">inset</ref>).</s><s>The dose of WAY 163909 predicted to decrease vertical activity by 50% (ID 50 ) was 2.3 mg/kg (Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">WAY 163909 dose-dependently suppresses cocaine self-administration</head><p><s>Rats (n = 8) readily acquired cocaine self-administration (0.25 mg/kg/0.1ml</s><s>infusion) to stability (i.e., seven infusions/hr on an FR 5 schedule for at least three sessions) and displayed &lt;10% variation in the number of infusions received (i.e., cocaine intake) (Fig. <ref type="figure" target="#fig_1">2A</ref>).</s><s>Across the last three sessions of stable self-administration, there was no main effect of session on the number of active [F (2,21) = 0.00, ns] or inactive lever responses [F (2,17) = 1.75, ns], or the number of infusions received [F (2,21) = 0.00, ns] (Fig. <ref type="figure" target="#fig_1">2A</ref>).</s><s>Average daily cocaine intake over the last three sessions of training was 4.4 ± 0.7 mg/kg.</s></p><p><s>An one-way ANOVA revealed a main effect of pretreatment on the number of active lever presses [F (5,42) = 2.92; p&lt; 0.05; Fig. <ref type="figure" target="#fig_1">2B</ref>, left panel] and number of cocaine infusions received across the entire 60-min session [F (5,42) = 2.79; p &lt; 0.05; Fig. <ref type="figure" target="#fig_1">2C,</ref><ref type="figure">left panel]</ref>.</s><s>No main effect was observed for the number of inactive lever presses [F (5,42) = 0.12; ns; Fig. <ref type="figure" target="#fig_1">2B]</ref>.</s><s>A priori comparisons revealed that pretreatment with 2 mg/kg of WAY 163909 significantly reduced the number of active lever presses (p&lt; 0.05; Fig. <ref type="figure" target="#fig_1">2B</ref>, left panel) as well as the number of cocaine infusions (p&lt; 0.05; Fig. <ref type="figure" target="#fig_1">2C</ref>, left panel) without altering the number of inactive lever presses (ns; Fig. <ref type="figure" target="#fig_1">2B</ref>).</s><s>The dose of WAY 163909 predicted to decrease lever presses for cocaine by 50% (ID 50 ) is 1.19 mg/kg (Table <ref type="table">2</ref>).</s><s>Pretreatment with the selective 5-HT 2C R antagonist SB 242084 (0.5 mg/kg i.p.) completely blocked the effects of WAY 163909 (2 mg/kg) on the number active lever presses (p &lt; 0.05; Fig. <ref type="figure" target="#fig_1">2B</ref>, right panel) and number of cocaine infusions received (p &lt;0.05; Fig. <ref type="figure" target="#fig_1">2C</ref>, right panel).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">WAY 163909 dose-dependently suppresses cocaine cue-evoked reinstatement</head><p><s>Rats (n = 34) readily acquired cocaine self-administration (0.75 mg/kg/0.1 ml infusion) in daily 180 min sessions to stability (i.e., seven infusions/hr on an FR 5 schedule for at least three sessions) and displayed &lt;10% variation in the number of infusions received (i.e., cocaine intake) (Fig. <ref type="figure" target="#fig_2">3A</ref>).</s><s>Across the last three sessions of stable self-administration on an FR 5 schedule, there was no main effect of session on the number of active [F (2,99) = 2.75, ns] or inactive lever responding [F (2,99) = 0.63, ns] or the number of infusions received [F (2,99) = 2.42, ns].</s><s>The rats were then separated into four groups for reinstatement sessions.</s><s>Cocaine intake did not differ significantly across groups of rats assigned to receive pretreatment with vehicle (34.6 ± 1.8 infusions/session) or WAY 163909 at doses of 0.5 mg/ kg (33.5 ± 1.8 infusions/session), 1 mg/kg (32 ± 1.2 infusions/session), or 1.5 mg/kg (31.9 ± 2.8 infusions/session) [F (3,30) = 0.62; ns].</s></p><p><s>A decrease in presses on the previously-active lever was observed across extinction sessions with all rats achieving the extinction criterion (&lt;15 active lever responses/session for three consecutive sessions) by session 12 of extinction training (data not shown).</s><s>A repeatedmeasures ANOVA revealed a main effect of extinction session on active [F (11,265) = 78.8;</s><s>p&lt; 0.05] and inactive lever presses [F (11,265) = 4.88; p&lt; 0.05] for all rats (n = 34) with both active and inactive lever presses decreasing across the extinction sessions (data not shown).</s><s>The "extinction baseline" was calculated as the mean total lever presses of all rats on the active (7.8 ± 0.6) or inactive lever (4.9 ± 0.9) during the final 60 min extinction session (Fig. <ref type="figure" target="#fig_2">3B</ref>, left).</s></p><p><s>Figure <ref type="figure" target="#fig_2">3</ref> Billustrates the effects of vehicle or WAY 163909 (0.5-1.5 mg/kg) pretreatment on reinstatement of responding supported by cues previously associated with cocaine availability.</s><s>Cocaine-trained rats readily reinstated active lever pressing across the 60-min reinstatement session (Fig. <ref type="figure" target="#fig_2">3B</ref>).</s><s>A main effect of pretreatment on active lever responding was observed [F (4,63) = 43.02;</s><s>p &lt;0.001; Fig. <ref type="figure" target="#fig_2">3B</ref>].</s><s>Significant decreases in active lever presses relative to vehicle were observed after pretreatment with WAY 163909 at doses of 0.5, 1 and 1.5 mg/kg (p&lt; 0.05; Fig. <ref type="figure" target="#fig_2">3B</ref>).</s><s>There was no main effect of pretreatment on inactive lever responding [F (4,61) = 1.66; ns; Fig. <ref type="figure" target="#fig_2">3B</ref>).</s><s>The latency to the first lever press following pretreatment with WAY 163909 was unaltered [F (3,30) = 0.95; ns] (data not shown).</s><s>The dose of WAY 163909 predicted to decrease lever presses for cocaine-paired cues by 50% (ID 50 ) is 0.5 mg/kg (Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">WAY 163909 dose-dependently suppresses sucrose self-administration</head><p><s>Rats (n = 8) readily acquired sucrose self-administration (45 mg sucrose pellet/response) to stability (i.e., 10 pellets/hr on an FR 5 schedule for at least three sessions) and displayed &lt;10% variation in the number of pellets received (i.e., pellet intake) (Fig. <ref type="figure" target="#fig_3">4A</ref>).</s><s>Across the last three sessions of stable self-administration on an FR5 schedule, there was no main effect of session on the number of active [F (2,21) = 0.01, ns] or inactive operant lever responses [F (2,21) = 1.8, ns] or the number of pellets received [F (2,21) = 0.03, ns].</s><s>Average daily sucrose intake over the last three sessions of training was 23.0 ± 3.4 pellets.</s></p><p><s>An one-way ANOVA revealed a main effect of pretreatment on the number of active lever presses [F (5,42) = 9.88 ; p&lt; 0.05; Fig. <ref type="figure" target="#fig_3">4B</ref>, left panel] and number of sucrose pellets received across the 60-min session [F (5,42) = 10.73 ; p&lt; 0.05; Fig. <ref type="figure" target="#fig_3">4C,</ref><ref type="figure">left panel]</ref>.</s><s>No main effect was observed for the number of inactive lever presses [F (5,42) = 1.66; ns; Fig. <ref type="figure" target="#fig_3">4B]</ref>.</s><s>A priori comparisons revealed that pretreatment with 1 or 2 mg/kg of WAY 163909 significantly reduced the number of active lever presses (p&lt; 0.05; Fig. <ref type="figure" target="#fig_3">4B</ref>, left panel) as well as the number of sucrose pellets received (p &lt; 0.05; Fig. <ref type="figure" target="#fig_3">4C</ref>, left panel), without altering the number of inactive lever presses (ns; Fig. <ref type="figure" target="#fig_3">4B</ref>).</s><s>The dose of WAY 163909 predicted to decrease lever presses for sucrose by 50% (ID 50 ) is 0.7 mg/kg (Table <ref type="table">2</ref>).</s><s>Pretreatment with the selective 5-HT 2C R antagonist SB 242084 (0.5 mg/kg i.p.) completely blocked the effects of WAY 163909 (2 mg/kg) on the number active lever presses (p &lt; 0.05; Fig. <ref type="figure" target="#fig_3">4B</ref>, right panel) and number of sucrose pellets received (p &lt; 0.05; Fig. <ref type="figure" target="#fig_3">4C</ref>, right panel).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">WAY 163909 does not alter sucrose cue-evoked reinstatement</head><p><s>Rats (n = 25) readily acquired sucrose self-administration (45 mg pellet) in daily 180 min sessions to stability (i.e., minimum 20 pellets/session on an FR 5 schedule for at least three sessions) and displayed &lt;10% variation in the number of pellets received (i.e., sucrose intake) (Fig. <ref type="figure" target="#fig_4">5A</ref>).</s><s>Across the last three sessions of stable self-administration on an FR 5 schedule, there was no main effect of session on the number of active [F (2,72) = 0.54, ns] or inactive lever responding [F (2,72) = 0.42, ns] or the number of pellets received [F (2,72) = 0.32, ns].</s><s>The rats were then separated into three groups for reinstatement sessions.</s><s>Sucrose intake did not differ significantly across groups of rats assigned to receive pretreatment with vehicle (26.4 ± 5.2 pellets/session) or WAY 163909 at doses of 0.5 mg/kg (24.2 ± 3.9 pellets/session), or 1.5 mg/kg (22.6 ± 3.9 pellets/session) [F (2, 22) = 0.34; ns].</s></p><p><s>A decrease in presses on the previously-active lever was observed across extinction sessions with all rats achieving the extinction criterion (&lt;15 active lever responses/session for three consecutive sessions) by session 34 of extinction training (data not shown).</s><s>A repeatedmeasures ANOVA revealed a main effect of extinction session on active <ref type="bibr">[F (33,311)</ref> = 19.19;</s><s>p&lt; 0.05] and inactive lever presses [F (33,311) = 3.99; p&lt; 0.05] across the extinction sessions for all rats (n = 25; data not shown).</s><s>The "extinction baseline" was calculated as the mean total lever presses of all rats on the active (7.9 ± 0.9) or inactive lever (5 ± 1.4) during the final 60 min extinction session (Fig. <ref type="figure" target="#fig_4">5B</ref>, left).</s></p><p><s>Figure <ref type="figure" target="#fig_4">5</ref> Billustrates the effects of WAY 163909 (0.5 and 1.5 mg/kg) pretreatment on reinstatement of responding supported by cues previously associated with sucrose availability.</s><s>Sucrose-trained rats readily reinstated active lever pressing across the 60-min reinstatement session (Fig. <ref type="figure" target="#fig_4">5B</ref>).</s><s>Amain effect of pretreatment on active lever responding was observed across the 60-min reinstatement session [F (3, 45) = 11.83;</s><s>p &lt;0.001; Fig. <ref type="figure" target="#fig_4">5B]</ref>.</s><s>A priori comparisons failed to reveal any significant differences in active lever presses relative to vehicle after pretreatment with any doses of WAY 163909 tested (ns; Fig. <ref type="figure" target="#fig_4">5B</ref>).</s><s>The one-way ANOVA revealed no main effect of pretreatment on inactive lever responding [F (3,46) = 2.61; ns; Fig. <ref type="figure" target="#fig_4">5B]</ref>.</s><s>The latency to the first lever press following pretreatment with WAY 163909 was unaltered [F (2,22) = 0.82; ns] (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">DISCUSSION</head><p><s>Our results demonstrate that the highly-selective and efficacious 5-HT 2C R agonist WAY 163909 dose-dependently reduced the reinforcing efficacy of cocaine and sucrose as assessed in parallel self-administration tasks conducted in freely-fed rats.</s><s>We also show for the first time that WAY 163909 dose-dependently reduced reinstatement elicited by exposure to cocaine-associated contextual cues, but failed to alter reinstatement of cueevoked sucrose-seeking in freely-fed rats.</s><s>Thus, selective stimulation of the 5-HT 2C R signaling decreases the reinforcing efficacy of cocaine and sucrose, but differentially alters the incentive-salience value of cocaine-versus sucrose-associated cues.</s></p><p><s>The dose of WAY 163909 predicted to decrease the reinforcing efficacy of cocaine (ID 50 = 1.19 mg/kg) by 50% was ~5-fold and ~2-fold lower than that predicted to suppress horizontal ambulation (ID 50 = 5.89 mg/kg) and vertical activity (ID 50 = 2.3 mg/kg), respectively (Table <ref type="table">2</ref>).</s><s>Although 5-HT 2C R agonists are reported to suppress both horizontal and vertical activity measures <ref type="bibr" target="#b24">(Halford, et al., 1997;</ref><ref type="bibr" target="#b21">Halberstadt, et al., 2009)</ref>, most pharmacological studies of 5-HT 2C R agonists (e.g., <ref type="bibr" target="#b20">Grottick, et al., 2000;</ref><ref type="bibr" target="#b14">Fletcher, et al., 2002)</ref> typically report horizontal activityas a comparative, independent measure in pharmacological assessments.</s><s>Horizontal ambulation and vertical activity often correlate, however, these measures have been behaviorally <ref type="bibr" target="#b69">(Walsh and Cummins, 1976;</ref><ref type="bibr" target="#b33">Lever, et al., 2006)</ref> and pharmacologically dissociated (e.g., <ref type="bibr" target="#b71">Wu, et al., 2005)</ref> and appear to be mediated by different brain regions <ref type="bibr" target="#b28">(Jackson, et al., 1975;</ref><ref type="bibr" target="#b33">Lever, et al., 2006)</ref>.</s><s>In general, vertical activity is more sensitive to pharmacological manipulation than is horizontal activity <ref type="bibr" target="#b48">(Prut and Belzung, 2003)</ref> and, consistent with the current study, <ref type="bibr" target="#b4">Brookshire and Jones (2009)</ref> demonstrated that the IC 50 for the preferential 5-HT 2C R agonist MK 212 to suppress vertical activity (IC 50 = ~0.93</s><s>mg/kg) was lower than that predicted to suppress horizontal activity (IC 50 = ~2.29 mg/kg).</s><s>In a review of the literature, we could not identify previous publications in which doses of a selective 5-HT 2C R agonist were assessed in parallel for efficacy to suppress both horizontal and vertical activity as well as operant responding for an abused drug and palatable reinforcer in freely-fed rats.</s><s>We uniquely present these observations that, coupled with the failure of WAY 163909 to significantly alter inactive lever presses at any dose, rule out the interpretation that the inhibitory effects of WAY 163909 on drug-seeking were due to a generalized suppression of behavior.</s><s>Thus, WAY 163909 presents an efficacy window between its effects on cocaine-taking and effects on locomotor activity which may reflect its greater selectivity as a 5-HT 2C R agonist relative to 5-HT 2A R and 5-HT 2B R (see below).</s><s>Furthermore, these data illustrate that the effects of MK 212 and Ro 60-0175 (Table <ref type="table" target="#tab_1">1</ref>) which have been profiled to suppress cocaine-taking are consistent with their actions preferentially as 5-HT 2C R agonists.</s></p><p><s>A primary therapeutic indication for selective 5-HT 2C R agonists is obesity and 5-HT 2C R agonists have been shown to suppress food intake and reduce weight gain in animals <ref type="bibr" target="#b9">(Clifton, et al., 2000;</ref><ref type="bibr" target="#b12">Dunlop, et al., 2005;</ref><ref type="bibr" target="#b16">Fletcher, et al., 2010;</ref><ref type="bibr" target="#b25">Hayashi, et al., 2005;</ref><ref type="bibr" target="#b26">Hewitt, et al., 2002)</ref> and most recently in humans <ref type="bibr" target="#b56">(Smith, et al., 2009;</ref><ref type="bibr" target="#b57">Smith, et al., 2010)</ref>.</s><s>We observed a potent WAY 163909-induced suppression of sucrose intake in freely-fed rats.</s><s>The ID 50 for WAY 163909 (0.7 mg/kg) in the present study is much lower than the effective dose reported to suppress feeding on powdered chow in fasted Sprague-Dawley rats (ID 50 = 2.93 mg/kg) and rats with diet-induced obesity (ID 50 = 5.19 mg/kg), but closer to the effective doses in obese Zucker rats (ID 50 =1.4</s><s>mg/kg) <ref type="bibr" target="#b12">(Dunlop, et al., 2005)</ref>.</s><s>Similarly, Ro 60-0175 suppressed sucrose intake at doses much lower than those observed to suppress feeding in fasted rats <ref type="bibr" target="#b25">(Hayashi, et al., 2005)</ref>.</s><s>Skinnerian tasks such as those employed here rely on the reinforcer (i.e., sucrose) to maintain operant responding and do not simply assay food consumption.</s><s>In the present study, the motivation to lever press for sucrose is based upon the efficacy and palatability of this reinforcer and the motivational state of rats that have free access to food.</s><s>Previous studies suggest that preferential 5-HT 2C R agonists reduce food intake by enhancing satiety <ref type="bibr" target="#b26">(Hewitt, et al., 2002;</ref><ref type="bibr" target="#b58">Somerville, et al., 2007)</ref>, an effect which may account for our observations, particularly in freely-fed rats in an operant task.</s><s>Stimulation of the 5-HT 2C R could also reduce the reinforcing efficacy of sucrose and thus the incentive-salience value of sucrose.</s><s>Most likely, stimulation of the 5-HT 2C R engages neural processes which control both satiety and reinforcing efficacy <ref type="bibr" target="#b16">(Fletcher, et al., 2010)</ref>.</s><s>Future studies are required to understand how the 5-HT 2C R signaling integrates neural process involved in motivation, satiety, palatability and reinforcing efficacy of food.</s></p><p><s>Associations between environmental (contextual) cues and consumption of rewarding stimuli (food or drug) become encoded memories and it is theorized that such cues can play an important role in relapse to drug use <ref type="bibr" target="#b34">(Lu, et al., 2005)</ref>, and possibly also in nonhomeostatic eating, i.e., food intake not driven by energy deficits <ref type="bibr" target="#b1">(Berthoud, 2004)</ref>.</s><s>In the present study, WAY 163909 potently suppressed reinstatement of cocaine-seeking with an 11-fold lower ID 50 dose (0.5 mg/kg) relative to the ID 50 dose (5.89 mg/kg) for suppression of horizontal ambulation and 5-fold lower ID 50 dose (2.3 mg/kg) relative to the ID 50 for suppression of vertical activity.</s><s>Interestingly, neither WAY 163909 (present study) nor Ro 60-1075 <ref type="bibr" target="#b6">(Burbassi and Cervo, 2008)</ref> inhibited sucrose-seeking during reinstatement.</s><s>However, a 5-HT 2C R agonist was shown to dose-dependently suppress cue-evoked food seeking in food-restricted mice <ref type="bibr" target="#b58">(Somerville, et al., 2007)</ref>.</s><s>The pharmacological suppression of drug-seeking during reinstatement is most often interpreted as reflecting decrements in the incentive-motivational value of the cue-elicited cocaine-seeking behavior <ref type="bibr" target="#b15">(Fletcher, et al., 2008;</ref><ref type="bibr" target="#b44">Nic Dhonnchadha, et al., 2009)</ref>.</s><s>Assessment and interpretation of the incentivemotivational value of non-drug-associated cues may be dependent on the palatability of the reinforcer (i.e., sucrose vs. food) as well as motivational state of rats (i.e., freely-fed vs. food-restricted) and additional studies are needed to elucidate this complex relationship.</s><s>This would suggest that while selective serotonin 5-HT 2C R activation suppresses the reinforcing efficacy of cocaine and sucrose, this signaling pathway is differentially engaged in the control of the incentive-motivational value of cocaine-and sucrose-associated cues.</s></p><p><s>The attenuation of cocaine-and sucrose-taking and cocaine-seeking behavior by WAY 163909 is attributable to a selective stimulation of the 5-HT 2C R based upon several lines of evidence.</s><s>WAY 163909 is fully efficacious as a 5-HT 2C R agonist, does not stimulate the 5-HT 2A R, and is only a weak 5-HT 2B R partial agonist at much greater concentrations than those that activate the 5-HT 2C R <ref type="bibr" target="#b12">(Dunlop, et al., 2005)</ref> (Table <ref type="table" target="#tab_1">1</ref>).</s><s>A low dose of the selective 5-HT 2C R antagonist SB 242084 completely reversed the inhibitory effects of WAY 163909 on cocaine-and sucrose-taking providing empirical evidence of behaviorally-relevant actions at the 5-HT 2C R signaling.</s><s>Rosenzweig-Lipson and colleagues have demonstrated the suppressive potency of WAY 163909 and the ability of SB 242084 to block WAY 163909generated behavioral effects in several assay systems, including those modeling the psychiatric disorders of anxiety, depression and schizophrenia <ref type="bibr">(Rosenzweig-Lipson, et al., 2007b;</ref><ref type="bibr" target="#b42">Navarra, et al., 2008;</ref><ref type="bibr" target="#b18">Grauer, et al., 2009;</ref><ref type="bibr" target="#b11">Dunlop, et al., 2006)</ref>.</s><s>In addition, WAY 163909 blocked cocaine-evoked hyperlocomotion as well as the associated enhancement of dopamine efflux in the nucleus accumbens <ref type="bibr">(Hughes et al., 2006)</ref>.</s><s>Interestingly, the high potency of WAY 163909 (0.5-2mg/kg) to suppress cocaine-taking and -seeking, as well as sucrose-taking, is similar to that seen to suppress impulsivity assessed in a five-choice serial reaction time task <ref type="bibr" target="#b42">(Navarra, et al., 2008)</ref> as well as aggressive behavior in rodents <ref type="bibr">(Rosenzweig-Lipson, et al., 2007b)</ref>.</s><s>Cocaine use is associated with increased impulsivity in animals <ref type="bibr" target="#b0">(Anastasio, et al., 2011;</ref><ref type="bibr" target="#b60">Stoffel and Cunningham, 2008)</ref> and cocaine-dependent subjects often present with impulsivity <ref type="bibr" target="#b38">(Moeller, et al., 2004;</ref><ref type="bibr" target="#b39">Moeller, et al., 2002;</ref><ref type="bibr" target="#b40">Moeller, et al., 2001;</ref><ref type="bibr" target="#b30">Kjome, et al., 2010)</ref> and there is recent evidence to suggest that impulsivity contributes to the development and maintenance of obesity <ref type="bibr" target="#b37">(Mobbs, et al., 2010)</ref> and binge eating disorder <ref type="bibr" target="#b37">(Mobbs, et al., 2010)</ref>.</s><s>Thus, selective, high efficacy 5-HT 2C R agonists may prove therapeutically useful in disorders characterized by impulsive traits.</s></p><p><s>The present observations support the assertion that selective activation of the 5-HT 2C R signaling may prove therapeutically useful to reduce craving for cocaine and extend abstinence <ref type="bibr" target="#b5">(Bubar and Cunningham, 2008)</ref>.</s><s>However, the progress of selective 5-HT 2C R agonists from preclinical evidence of efficacy to verification of safety and efficacy as psychotherapeutic medications in humans has been slow.</s><s>Clinical trials evaluating the first selective 5-HT 2C R agonist, lorcaserin (APD 356, Arena Pharmaceuticals), for weight reduction were successfully completed <ref type="bibr" target="#b56">(Smith, et al., 2009;</ref><ref type="bibr" target="#b57">Smith, et al., 2010)</ref>.</s><s>Lorcaserin, which exhibits ~15-fold and ~100-fold greater potency to stimulate the 5-HT 2C R over the homologous 5-HT 2A R and 5-HT 2B R, respectively, effectively suppressed food intake, reduced weight gain, and was well tolerated by obese subjects <ref type="bibr" target="#b56">(Smith, et al., 2009;</ref><ref type="bibr" target="#b57">Smith, et al., 2010)</ref>.</s><s>Further, when evaluated in polydrug users, the doses shown to be therapeutic in obesity <ref type="bibr" target="#b56">(Smith, et al., 2009;</ref><ref type="bibr" target="#b57">Smith, et al., 2010)</ref> were well-tolerated, exhibited low abuse liability, and were not associated with notable neurocognitive or perceptual effects <ref type="bibr" target="#b55">(Schram, et al., 2009)</ref>.</s><s>The selective 5-HT 2C R agonist vabicaserin has been evaluated in clinical trials to establish its efficacy and safety in subjects with an acute exacerbation of schizophrenia.</s><s>The development of two selective 5-HT 2C R agonists which advanced to clinical trials opens the door to implementation of clinical research to evaluate these compounds as innovative pro-abstinence, anti-relapse therapeutics for stimulant addiction, eating disorders and obesity.</s></p><p><s>In conclusion, the 5-HT 2C R is a functionally important regulator of the neural substrates that control the rewarding efficacy of a drug (cocaine) and natural (sucrose) reinforcer as well as the incentive-salience value of cocaine-associated cues.</s><s>WAY 163909 is a potent, selective and efficacious 5-HT 2C R agonist which presents a favorable efficacy index between doses useful in inhibiting self-administration/reinstatement and doses which suppress locomotor activity.</s><s>This compound will prove useful to further tease apart the precise involvement of 5-HT 2C R neurocircuitry in reward and motivation as well as the learning and memory processes that carry the encoding for associations between environmental (contextual) cues and consumption of rewarding stimuli (food or drug).</s><s>A more complete preclinical evaluation of these questions will ultimately allow educated proof-of-concept trials to test the concept that selective 5-HT 2C R agonists may be useful as adjunctive therapy in such chronic disorders marked by impulsive drug and/or food intake.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research Highlights</head><p><s>• Selective 5-HT 2C R activation potently decreases the reinforcing efficacy of cocaine and sucrose in freely-fed rats        Published studies employed radioligand binding assays to establish the affinity (K i ) and efficacy (Emax) of MK 212 <ref type="bibr" target="#b31">(Knight, et al., 2004;</ref><ref type="bibr" target="#b10">Cussac, et al., 2002;</ref><ref type="bibr" target="#b47">Porter, et al., 1999)</ref> and Ro 60-0175 for the 5-HT 2 R subtypes in h5-HT 2A R-or h5-HT 2C R-transfected Human Embryonic Kidney (HEK)-293 <ref type="bibr" target="#b31">(Knight, et al., 2004</ref>) and h5-HT 2A R-, h5-HT 2B R-, or h5-HT 2C R-transfected Chinese Hamster Ovary (CHO)-K1 clonal cell lines <ref type="bibr" target="#b47">(Porter, et al., 1999;</ref><ref type="bibr" target="#b10">Cussac, et al., 2002)</ref> while the affinity of WAY 163909 for each h5-HT 2 R subtype was established in CHO-K1 cells <ref type="bibr" target="#b12">(Dunlop, et al., 2005)</ref>.</s><s>The efficacy of MK 212 <ref type="bibr" target="#b47">(Porter, et al., 1999)</ref>, Ro 60-0175 <ref type="bibr" target="#b47">(Porter, et al., 1999)</ref> and WAY 163909 <ref type="bibr" target="#b12">(Dunlop, et al., 2005)</ref> was established in agonist-stimulated mobilization of intracellular calcium in CHO-K1 cells with a fluorometric imaging plate reader; the Emax is expressed as a percentage of the maximal response to 5-HT.</s><s>MK 212 exhibits did not exhibit efficacy (IC 50 &gt; 1 µM) for the 5-HT 2A R <ref type="bibr" target="#b31">(Knight, et al., 2004)</ref>.</s></p><p><s>Ro 60-0175 did not exhibit efficacy (IC 50 &gt; 1 µM) for a multitude of proteins with the highest affinity for β 2 adrenoceptor (β 2 -noradrenergic receptor; IC 50 = 251; <ref type="bibr" target="#b36">Martin, et al., 1998)</ref>.</s><s>WAY 163909 exhibited modest affinity for the dopamine D 4 R (K i =245 nM), 5-HT 7 R (K i =343 nM) and α 1 adrenoceptor (K i =665 nM; <ref type="bibr" target="#b12">Dunlop, et al., 2005)</ref>.</s></p><p><s>Neuropharmacology.</s><s>Author manuscript; available in PMC 2012 September 1.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>WAY 163909 evokes a dose-dependent suppression of horizontal ambulation and vertical activity [A] The time course of horizontal ambulation is divided into 15 min time bins across the 60 min session; [A, Inset] the mean total horizontal ambulation (counts/60 min) (± SEM) is represented following administration of vehicle (saline; Veh) or WAY 163909 (WAY; 0.3, 1, 3 or 10 mg/kg, i.p.).</s><s>[B] The time course of vertical activity is divided into 15 min time bins across the 60 min session; [B, Inset] the mean total vertical activity (counts/60 min) (± SEM) is represented following administration of vehicle (saline; Veh) or WAY 163909 (WAY; 0.3, 1, 3, or 10 mg/kg, i.p.).</s><s>*p&lt; 0.05 vs. Veh.</s></p></div></figDesc><graphic coords="19,198.48,61.00,275.04,503.56" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. WAY 163909 dose-dependently suppresses cocaine self-administration [A] Mean responses (+/-SEM) on the active (black circles) or inactive lever (white circles), and total number of cocaine infusions (+/-SEM; gray circles) are presented for the acquisition phase of cocaine self-administration training under FR1 -FR5 schedules of reinforcement.</s><s>Active lever responses resulted in the delivery of an intravenous cocaine infusion (0.25 mg/kg/0.1 ml infusion) and simultaneous presentation of the cocaine-paired cues.</s><s>[B] Mean responses (+/-SEM) on the active (black bars) or inactive lever (white bars) or [C] mean total cocaine infusions (+/-SEM; gray bars) following pretreatment with vehicle (saline; Veh) or WAY 163909 (0.5, 1 or 2 mg/kg, i.p., 15 min) (left panel) or following pretreatment with the 5-HT 2C R antagonist SB 242084 (0.5 mg/kg, i.p., 15 min) plus vehicle (saline; Veh) or WAY 163909 (2 mg/kg, i.p.) (right panel) during the cocaine self-administration maintenance phase.</s><s>Active lever responses resulted in the delivery of an intravenous cocaine infusion (0.25 mg/kg/0.1 ml infusion) according to an FR 5 schedule and simultaneous presentation of cocaine-paired cues.</s><s>*p &lt; 0.05 vs. Veh; ^p &lt; 0.05 vs. WAY 163909 (2 mg/kg).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. WAY 163909 dose-dependently suppresses cocaine cue-evoked reinstatement [A] Mean responses (+/-SEM) on the active (black circles) or inactive lever (white circles), and the total number of cocaine infusions (+/-SEM; gray circles) are presented for the acquisition phase of cocaine self-administration training under FR1 -FR5 schedules of reinforcement.</s><s>Active lever responses resulted in the delivery of an intravenous cocaine infusion (0.75 mg/kg/0.1 ml infusion) and simultaneous presentation of the cocaine-paired cues.</s><s>[B] Mean (+/-SEM) total number of responses on the active (black bars) or inactive lever (white bars) following extinction ("Extinction Baseline") and upon pretreatment with vehicle (saline; Veh) or WAY 163909 (0.5, 1, or 1.5 mg/kg, i.p.) on the test day for reinstatement of extinguished cocaine-seeking behavior.</s><s>Reinstatement was initiated by a single non-contingent presentation of cocaine-paired cues (pump and stimulus light).</s><s>Each active lever press resulted in the presentation of the conditioned stimuli in the absence of cocaine delivery.</s><s>*p &lt; 0.05 vs. Extinction; ^p &lt; 0.05 vs. Veh.</s></p></div></figDesc><graphic coords="21,305.08,61.00,61.84,80.64" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. WAY 163909 dose-dependently suppresses sucrose self-administration [A] Mean responses (+/-SEM) on the active (black circles) or inactive lever (white circles), and total number of sucrose pellets (+/-SEM; gray circles) are presented for the acquisition phase of cocaine self-administration training under FR1 -FR5 schedules of reinforcement.</s><s>Active lever responses resulted in the delivery of a single sucrose pellet (45 mg) and simultaneous presentation of the sucrose-paired cues.</s><s>[B] Mean responses (+/-SEM) on the active (black bars) or inactive lever (white bars) or [C] mean total sucrose pellets (+/-SEM; gray bars) following pretreatment with vehicle (saline; Veh) or WAY 163909 (0.5, 1 or 2 mg/kg, i.p., 15 min) (left panel) or following pretreatment with the 5-HT 2C R antagonist SB 242084 (0.5 mg/kg, i.p., 15 min) plus vehicle (saline; Veh) or WAY 163909 (2 mg/kg, i.p.)</s></p></div></figDesc><graphic coords="22,217.20,61.00,237.60,503.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. WAY 163909 does not alter sucrose cue-evoked reinstatement [A] Mean responses (+/-SEM) on the active (black circles) or inactive lever (white circles), and the total number of sucrose pellets (+/-SEM; gray circles) are presented for the acquisition phase of sucrose self-administration under FR1 -FR5 schedules of reinforcement.</s><s>Active lever responses resulted in the delivery of a single sucrose pellet (45 mg) and simultaneous presentation of the sucrose-paired cues.</s><s>[B] Mean (+/-SEM) total number of responses on the active (filled bars) or inactive levers (open bars) following extinction ("Extinction Baseline") and upon pretreatment with vehicle (saline; Veh) or WAY 163909 (0.5 or 1.5 mg/kg, i.p.) on the test day for reinstatement of extinguished sucrose-seeking behavior.</s><s>Reinstatement was initiated by a single non-contingent presentation of sucrose-paired cues (pump and stimulus light).</s><s>Each active lever press resulted in the presentation of the conditioned stimuli in the absence of sucrose pellet delivery.</s><s>*p &lt; 0.05 vs. Extinction.</s></p></div></figDesc><graphic coords="24,306.84,61.00,58.32,80.31" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p><s>Neuropharmacology.</s><s>Author manuscript; available in PMC 2012 September 1.</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>This research was supported by the <rs type="funder">National Institute on Drug Abuse</rs> grants <rs type="grantNumber">P20 DA024157</rs> (<rs type="affiliation">KAC, SRG, FGM</rs>), <rs type="grantNumber">R01 DA006511</rs> (KAC), <rs type="grantNumber">K02 DA000403</rs> (FGM), <rs type="grantNumber">K05 DA020087</rs> (KAC), and the <rs type="grantName">Jeane B. Kempner Postdoctoral Scholar Award</rs> (NCA).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_ejbPSgG">
					<idno type="grant-number">P20 DA024157</idno>
				</org>
				<org type="funding" xml:id="_jMcNyZC">
					<idno type="grant-number">R01 DA006511</idno>
				</org>
				<org type="funding" xml:id="_mDRdG6y">
					<idno type="grant-number">K02 DA000403</idno>
				</org>
				<org type="funding" xml:id="_bktzc9j">
					<idno type="grant-number">K05 DA020087</idno>
					<orgName type="grant-name">Jeane B. Kempner Postdoctoral Scholar Award</orgName>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The serotonin 5-HT 2A receptor: Association with inherent and cocaine-evoked behavioral disinhibition in rats</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Anastasio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Stoffel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bubar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Moeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Pharmacol</title>
		<imprint>
			<date type="published" when="2011-04-14">2011 Apr 14</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Neural control of appetite: cross-talk between homeostatic and non-homeostatic systems</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Berthoud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Appetite</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="315" to="317" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15527935</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Behavioural analysis of feeding: implications for the pharmacological manipulation of food intake in animals and man</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tombros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Latham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="319" to="326" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
	<note>PubMed: 6111812</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">RS-102221: A novel high affinity and selective, 5-HT 2C receptor antagonist</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bonhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Weinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Desouza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Mcneeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Szczepanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Fontana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trinh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Flippin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Eglen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="621" to="629" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9225287</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Brookshire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="194" to="203" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19698737</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prospects for serotonin 5-HT 2 R pharmacotherapy in psychostimulant abuse</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bubar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Brain Res</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="319" to="346" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18772040</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Stimulation of serotonin(2C) receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats</title>
		<author>
			<persName><forename type="first">S</forename><surname>Burbassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cervo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="15" to="27" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 17899022</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Acquisition of IV amphetamine and cocaine self-administration in rats as a function of dose</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Lac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="206" to="214" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9084058</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Preexposure to environmental cues predictive of food availability elicits hypothalamic-pituitary-adrenal axis activation and increases operant responding for food in female rats</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cifani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanoncelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tessari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Righetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Di</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ciccocioppo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Massi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Melotto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addict Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="397" to="407" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19413564</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dourish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="256" to="267" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11105935</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cussac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Newman-Tancredi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Quentric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carpentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Poissonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Parmentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn Schmiedebergs Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="242" to="252" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11882920</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dunlop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Marquis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Drug Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">17227285</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A novel 5-HT2C receptor selective agonist with anorectic activity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dunlop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Sabb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mazandarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kalgaonker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Shukhina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sukoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schechter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="862" to="869" />
			<date type="published" when="2005">7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta. 2005</date>
		</imprint>
	</monogr>
	<note>1,4]diazepino[ 6,7,1hi]indole. PubMed: 15705738</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Burn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Corjay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Valentine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Abbaszade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hollis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Largent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hartig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Hollis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Meunier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Robichaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Robertson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="75" to="81" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10617681</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Differential effects of the 5-HT2A receptor antagonist M100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="576" to="586" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The 5-HT(2C) receptor agonist RO 60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine and contextual cues</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rizos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sinyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tampakeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1402" to="1412" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sinyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="170" to="178" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20624416</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tampakeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sinyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Slassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Isaac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="259" to="267" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19501602</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Grauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Navarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Logue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huselton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Comery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Marquis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="37" to="48" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19107466</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Activation of 5-HT2C receptors reduces the locomotor and rewarding effects of nicotine</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Corrigall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="292" to="298" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11605085</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Studies to investigate the role of 5-HT(2C) receptors on cocaine-and food-maintained behavior</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="page" from="1183" to="1191" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11082456</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van Dh, Ruderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">B</forename><surname>Risbrough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Powell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1958" to="1967" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Pharmacological management of appetite expression in obesity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Halford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Boyland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Kirkham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Harrold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Endocrinol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="255" to="269" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20234354</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Neuropharmacology of human appetite expression</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Halford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Harrold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dev Disabil Res Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="158" to="164" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18646016</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Halford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Lawton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blundell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="41" to="46" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 8981607</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sasamata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miyata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="241" to="249" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15719229</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Serotonin 2C receptor agonists and the behavioural satiety sequence in mice</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Hewitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dourish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="691" to="700" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11888560</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Ouagazzal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="459" to="466" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11399662</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Anden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dahlstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacologia</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="139" to="149" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
	<note>PubMed: 1215445</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Memory and addiction: shared neural circuitry and molecular mechanisms</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Kelley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="161" to="179" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15450168</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Relationship between impulsivity and decision making in cocaine dependence</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Kjome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Prasla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Swann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Moeller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="299" to="304" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20478631</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Pharmacological characterisation of the agonist radioligand binding site of 5-HT 2A , 5-HT 2B and 5-HT 2C receptors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Misra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Quirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Benwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Revell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bickerdike</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn-Schmiedeberg&apos;s Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="114" to="123" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15322733</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the striaterminalis or the central nucleus of the amygdala</title>
		<author>
			<persName><forename type="first">F</forename><surname>Leri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Flores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rodaros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="5713" to="5718" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12097523</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Rearing on hind legs, environmental novelty, and the hippocampal formation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="111" to="133" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16703946</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Central amygdala ERK signaling pathway is critical to incubation of cocaine craving</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Hope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dempsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bossert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shaham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Neurosci</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">15657599</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Increased self-administration of d-amphetamine after destruction of 5-hydroxytryptaminergic neurons</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Lyness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Friedle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Moore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="937" to="941" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">5-HT 2C receptor agonists: Pharmacological characteristics and therapeutic potential</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jenck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Moreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mutel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Sleight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hhg</forename><surname>Berendsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cle</forename><surname>Broekkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gsf</forename><surname>Ruigt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kohler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Delft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aml</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology &amp; Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="913" to="924" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9694950</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Obesity and the four facets of impulsivity</title>
		<author>
			<persName><forename type="first">O</forename><surname>Mobbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Crepin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thiery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Golay</surname></persName>
		</author>
		<author>
			<persName><surname>Van Der Lm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Patient Educ Couns</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="372" to="377" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20399590</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">P300 eventrelated potential amplitude and impulsivity in cocaine-dependent subjects</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Moeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Barratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Dougherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Reilly</forename><forename type="middle">El</forename><surname>Mathias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Swann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychobiology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="167" to="173" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15292673</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Increased impulsivity in cocaine dependent subjects independent of antisocial personality disorder and aggression</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Moeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Dougherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Barratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Oderinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Mathias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Swann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="105" to="111" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12167556</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The impact of impulsivity on cocaine use and retention in treatment</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Moeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Dougherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Barratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Swann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grabowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Subst Abuse Treat</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="193" to="198" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11777668</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ms-Deutsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shaham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Neurobiol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="18" to="45" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19497349</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test</title>
		<author>
			<persName><forename type="first">R</forename><surname>Navarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Comery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Day</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Brain Res</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page">18191235</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Neisewander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Acosta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Pharmacol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="791" to="800" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17989517</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat selfadministration model</title>
		<author>
			<persName><forename type="first">Nic</forename><surname>Dhonnchadha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Stutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Neurosci</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="382" to="396" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19331461</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Nichols</forename><forename type="middle">De</forename><surname>Hallucinogens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="131" to="181" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14761703</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Stimulation of medial prefrontal cortex serotonin 2C 5-HT 2C receptors attenuates cocaineseeking behavior</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Pentkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Duke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Pockros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Teer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Neisewander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2037" to="2048" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Benwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lamb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Malcolm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Revell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sheardown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="13" to="20" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10498829</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review</title>
		<author>
			<persName><forename type="first">L</forename><surname>Prut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Belzung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="page" from="3" to="33" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12600700</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Ratkowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Reedy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="575" to="582" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 3567290</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Goulding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Dell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Mead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Coufal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Parsons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Tecott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="10039" to="10045" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12427861</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scearce-Levie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hiroi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Castanon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Crabbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Nestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">393</biblScope>
			<biblScope unit="page" from="175" to="178" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9603521</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">5-HT2C receptor agonists as an innovative approach for psychiatric disorders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dunlop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Marquis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug News Perspect</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">18176661</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenzweig-Lipson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sabb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lucki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Malberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Cryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sukoff</forename><surname>Rizzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dunlop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Marquis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page">17297636</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Drugs and valvular heart disease</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page">17202450</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Abuse potential evaluation of lorcaserin, a selective and potent agonist at the serotonin 2C (5-HT 2C ) receptor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Schram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Schoedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Shazer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Sellers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">healthy male and female recreational polydrug users. Amer. Coll. Neuropsychopharmacol 48th Annual Meeting; American College of Neuropsychopharmacology Annual Meeting 48th Annual Meeting</title>
		<imprint>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Prosser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Donahue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Morgan</forename><surname>Me</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Shanahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity (Silver Spring)</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="494" to="503" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19057523</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Multicenter, placebo-controlled trial of lorcaserin for weight management</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Weissman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stubbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Shanahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="245" to="256" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20647200</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain cfosimmunoreactivity in mice</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Somerville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Horwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Neurosci</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="3115" to="3124" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17561825</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Eating disorders and the serotonin connection: state, trait and developmental effects</title>
		<author>
			<persName><forename type="first">H</forename><surname>Steiger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychiatry Neurosci</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="20" to="29" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14719047</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The relationship between the locomotor response to a novel environment and behavioral disinhibition in rats</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Stoffel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page">17997051</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title level="m" type="main">Manual of Pharmacologic Calculations with Computer Programs</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Tallarida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Murray</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1987">1987</date>
			<publisher>Springer-Verlag</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors [see comments]</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Tecott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Akana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Strack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Lowenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Dallman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julius</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page">7700379</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Menzaghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Reyes-Saldana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Espitia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yuskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Whelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Al-Shamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chalmers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Behan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="577" to="587" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18252809</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">An investigation of the role of 5-HT(2C) receptors in modifying ethanol self-administration behaviour</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Tomkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Joharchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tampakeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="735" to="744" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11888565</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Metabolism of vabicaserin in mice, rats, dogs, monkeys, and humans</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chandrasekaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Demaio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Espina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scatina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Metab Dispos</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="2266" to="2277" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20739639</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Species differences in the formation of vabicaserincarbamoylglucuronide</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chandrasekaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Demaio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Poola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Burghart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hultin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scatina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Metab Dispos</title>
		<imprint>
			<biblScope unit="volume">2010</biblScope>
			<biblScope unit="page" from="581" to="590" />
		</imprint>
	</monogr>
	<note>PubMed: 20032194</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Serotonin depletion attenuates cocaine seeking but enhances sucrose seeking and the effects of cocaine priming on reinstatement of cocaine seeking in rats</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Tran-Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Bellew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Grote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Neisewander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="340" to="348" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11605092</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Reduced satiating effect of d-fenfluramine in serotonin 5-HT 2C receptor mutant mice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dourish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Tecott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="309" to="314" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10353435</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">The open-field test: a critical review</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Cummins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Bull</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="482" to="504" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
	<note>PubMed: 17582919</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Evidence for an involvement of 5-hydroxytryptaminergic neurones in the maintenance of operant behaviour by positive reinforcement</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Wogar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bradshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Szabadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page">1720896</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Strong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="256" to="263" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15290006</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
